


# IN THE CLAIMS


## Amended Claims

1. (Presently Amended) A compound of the formula I




in which

A



or



R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>2</sub>-C<sub>20</sub>-alkenyl, C<sub>2</sub>-C<sub>20</sub>-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, or arylalkyl, heteroarylalkyl, wherein R<sup>1</sup> is unsubstituted or substituted with at least one substituent chosen from R<sup>6</sup>,

R<sup>2</sup> is C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>2</sub>-C<sub>20</sub>-alkenyl, C<sub>2</sub>-C<sub>20</sub>-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, or

alkylheteroaryl, arylalkyl, or heteroarylalkyl wherein R<sup>2</sup> is unsubstituted or substituted with at least one substituent chosen from R<sup>6</sup>,

or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen atom bearing them, form a 3-8-membered ring which may optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S, and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R<sup>6</sup> radical,

R<sup>3</sup> is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, ~~or~~ -CO-aryl, or -CO-heteroaryl,

R<sup>4</sup> is C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>2</sub>-C<sub>20</sub>-alkenyl, C<sub>2</sub>-C<sub>20</sub>-alkynyl, cycloalkyl with three to eight ring carbon atoms, cycloalkenyl with three to eight ring carbon atoms, cycloalkylalkyl with five to six ring carbon atoms, aryl, heteroaryl, alkylaryl, alkylheteroaryl, arylalkyl, heteroarylalkyl, -CO-O-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-alkyl, ~~-CO-O-aryl~~, -CO-aryl or -CO-heteroaryl wherein R<sup>4</sup> is unsubstituted or substituted with at least one substituent chosen from R<sup>7</sup>,

R<sup>5</sup> is hydrogen, -CO-alkyl, -CO-alkylaryl, -CO-alkylheteroaryl, ~~or~~ -CO-aryl, or -CO-heteroaryl,

R<sup>6</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>7</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, O-CO-O-aryl, O-CO-O-heteroaryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>8</sup> is hydrogen or C<sub>1</sub>-C<sub>20</sub>-alkyl, and

R<sup>9</sup> is hydrogen, C<sub>1</sub>-C<sub>20</sub>-alkyl, ~~or~~ aryl, or heteroaryl,

wherein aryl groups are carbocyclic aryl groups,  
wherein heteroaryl groups are 5- to 7-membered unsaturated heterocycles  
comprising 1-4 heteroatoms chosen from O, N, and S,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form, ~~or a mixture of any such compounds in any ratio.~~

2. (Presently Amended) The compound of the formula I as claimed in claim 1, in which

R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, ~~or~~ (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, (C<sub>1</sub>-C<sub>3</sub>)-alkylheteroaryl, ~~or~~ arylalkyl, or heteroarylalkyl, wherein R<sup>1</sup> is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R<sup>6</sup>,

R<sup>2</sup> is (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>3</sub>-C<sub>8</sub>)-cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, ~~or~~ (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, or (C<sub>1</sub>-C<sub>3</sub>)-alkylheteroaryl wherein R<sup>2</sup> is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R<sup>6</sup>,

or R<sup>1</sup> and R<sup>2</sup> may, together with the nitrogen atom bearing them, form a 3-8-membered ring, wherein said 3-8-membered ring optionally comprises 0, 1 or 2 further heteroatoms chosen from N, O, and S and wherein said 3-8-membered ring is unsubstituted or substituted by at least one substituent chosen from R<sup>6</sup> radical,

R<sup>3</sup> is hydrogen, -CO-(C<sub>1</sub>-C<sub>7</sub>)-alkyl, -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, ~~or~~ -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkylheteroaryl, -CO-aryl, or -CO-heteroaryl,

R<sup>4</sup> is (C<sub>1</sub>-C<sub>10</sub>)-alkyl, aryl, heteroaryl, (C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, (C<sub>1</sub>-C<sub>3</sub>)-alkylheteroaryl -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, ~~or~~ -CO-aryl or -CO-heteroaryl, wherein R<sup>4</sup> is unsubstituted or the alkyl radicals are substituted with at least one substituent chosen from R<sup>7</sup>,

R<sup>5</sup> is hydrogen, CO-(C<sub>1</sub>-C<sub>7</sub>)-alkyl, -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkylaryl, -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkylheteroaryl, ~~or -CO-aryl, or -CO-heteroaryl,~~

R<sup>6</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-CO-aryl, -O-CO-heteroaryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>7</sup> is -F, -OH, -O-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-phenyl, -O-CO-(C<sub>1</sub>-C<sub>10</sub>)-alkyl, -O-CO-aryl, O-CO-heteroaryl, -NR<sup>8</sup>R<sup>9</sup>, oxo, phenyl, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CO-O-aryl, -CO-O-heteroaryl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

R<sup>8</sup> is hydrogen or (C<sub>1</sub>-C<sub>5</sub>)-alkyl, and

R<sup>9</sup> is hydrogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or phenyl,

wherein each aryl group is ~~chosen from phenyl or, naphthyl and heteroaryl groups,~~ and

wherein said heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising 1-4 heteroatoms chosen from O, N, and S,

wherein said phenyl, naphthyl and heteroaryl groups are substituted groups which are substituted by at least one substituent chosen from halogen, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or phenyl, -OH, -O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, -N<sup>8</sup>R<sup>9</sup>, -NO<sub>2</sub>, -CO-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -CF<sub>3</sub>, -CN, -CONR<sup>8</sup>R<sup>9</sup>, -COOH, -CO-O-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -S(O)<sub>n</sub>-(C<sub>1</sub>-C<sub>5</sub>)-alkyl, -SO<sub>2</sub>-NR<sup>8</sup>R<sup>9</sup>,

~~wherein said heteroaryl groups are 5- to 7-membered unsaturated heterocycles comprising at least one or more heteroatom chosen from O, N, S, and~~

wherein n is 0, 1 or 2,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form, ~~or a mixture of any such compounds in any ratio.~~

3. (Presently Amended) A compound of the formula I as claimed in claim 1, in which

R<sup>1</sup> is hydrogen, unsubstituted (C<sub>2</sub>-C<sub>4</sub>)-alkyl, substituted (C<sub>2</sub>-C<sub>4</sub>)-alkyl which is substituted by at least one R<sup>6</sup>, or (C<sub>1</sub>-C<sub>2</sub>)-alkyl aryl or (C<sub>1</sub>-C<sub>2</sub>)-alkylheteroaryl,

R<sup>2</sup> is unsubstituted (C<sub>2</sub>-C<sub>4</sub>)-alkyl, substituted (C<sub>2</sub>-C<sub>4</sub>)-alkyl which is substituted by at least one R<sup>6</sup>, or cyclohexylmethyl or (C<sub>1</sub>-C<sub>2</sub>)-alkylaryl or (C<sub>1</sub>-C<sub>2</sub>)-alkylheteroaryl,

or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen atom bearing them, form a 5-7-membered ring wherein said 5-7-membered ring optionally comprises an additional heteroatom chosen from N, O, and S,

R<sup>3</sup> is hydrogen, -CO-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, ~~or~~ -CO-aryl or -CO-heteroaryl,

R<sup>4</sup> is aryl, heteroaryl, (C<sub>1</sub>-C<sub>5</sub>)-alkyl, ~~or~~ -CO-O-aryl or -CO-heteroaryl, wherein R<sup>4</sup> is unsubstituted or substituted with at least one substituent chosen from R<sup>7</sup>,

R<sup>5</sup> is hydrogen,

R<sup>6</sup> is -OH, -O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -NR<sup>8</sup>R<sup>9</sup> or -COOH, and

R<sup>7</sup> is -OH, (C<sub>1</sub>-C<sub>10</sub>)-alkyloxy, phenoxy or oxo,

wherein each aryl group is chosen from phenyl, thiophenyl, furyl or pyridyl,

wherein said heteroaryl groups are chosen from thiophenyl, furyl and pyridyl,

wherein said phenyl, thiophenyl, furyl or pyridyl groups are unsubstituted groups or substituted groups which are substituted by at least one substituent chosen from (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen, (C<sub>1</sub>-C<sub>3</sub>)-alkyloxy and (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy, and

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form, ~~or a mixture of any such compounds in any ratio.~~

4. (Presently Amended) A compound of the formula I as claimed in claim 1, in which

R<sup>1</sup> is arylmethyl,-

R<sup>2</sup> is arylmethyl or cyclohexylmethyl,

or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen atom bearing them, form a pyrrolidine, piperidine, morpholine, dimethylmorpholine, thiomorpholine, or N-(C<sub>1</sub>-C<sub>2</sub>)-alkylpiperazine ring,

R<sup>3</sup> is hydrogen,

R<sup>4</sup> is alkyl or 1,2-dihydroxypropyl,

R<sup>5</sup> is hydrogen

R<sup>6</sup> is -OH, -O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -NR<sup>8</sup>R<sup>9</sup> or -COOH, and

R<sup>7</sup> is -OH, decyloxy or phenoxy,

wherein each aryl group is chosen from unsubstituted phenyl or substituted phenyl, which is substituted by at least one substituent chosen from (C<sub>1</sub>-C<sub>3</sub>)-alkyl, halogen and (C<sub>1</sub>-C<sub>3</sub>)-alkyloxy and (C<sub>1</sub>-C<sub>2</sub>)-alkylenedioxy,

or a physiologically acceptable salt, hydrate, or ester thereof, in any stereoisomeric or tautomeric form, ~~or a mixture of any such compounds in any ratio.~~

5. (Presently Amended) The compound as claimed in claim 1, which is a tetrahydropteridine wherein R<sup>4</sup> is aryl, heteroaryl, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or -CO-O-aryl or -CO-O-(heteroaryl), and wherein said R<sup>4</sup> is unsubstituted or substituted with at least one substituent chosen from R<sup>7</sup>.

6. (Presently Amended) The compound as claimed in claim 1, which is a pteridine wherein

$R^1$  and  $R^2$  are each, independently alkyl or aryl, or heteroaryl, or

$R^1$  is hydrogen and  $R^2$  is cycloalkyl or cycloalkylalkyl, and

wherein  $R^4$  is aryl, (C<sub>1</sub>-C<sub>5</sub>)-alkyl or -CO-O-aryl or -CO-O-(heteroaryl), wherein said  $R^4$  is unsubstituted or substituted with at least one substituent chosen from  $R^7$ .


7. (Presently Amended) A pharmaceutical comprising ~~at least one of the~~ compounds as claimed in claim 1 and ~~at least one~~ additional ingredient chosen from conventional excipients and additives.

8. (Presently Amended) A method of treating or preventing strokes, ~~pathological falls in blood pressure, ulcerative colitis, transplant rejection reactions, nephritis, reperfusion damage, infarct damage, cardiomyopathy, Alzheimer's disease, epilepsy, migraine and neuritis of varying etiology~~ comprising administration of at least one pharmaceutical of claim 7 to a patient in need thereof.

9. (Cancelled)

10. (Cancelled)

11. (Previously Presented) A process for preparing the compound as claimed in claim 1 comprising reacting a compound of the formula II




(II)


with a compound of the formula III




which results in a compound of the formula IV



wherein the compound of formula IV is converted to a compound of formula V by catalytic hydrogenation



and wherein a compound of formula V is reacted with a compound of the formula VI



to give a compound of formula I.



12 - 14. (Cancelled).